electroCore, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
electroCore reported Q2 2026 net sales of $9.5M (up 28% YoY from $7.4M), driven by VA prescription gammaCore growth (~11% YoY) and Quell acceleration (~700% YoY to $1.3M). Net loss improved to $3.1M (from $3.7M); Adjusted EBITDA loss improved 26% to $1.8M. Company raised full-year 2026 guidance to >30% growth and projects positive Adjusted EBITDA by Q3 2027. Restructured sales organization: doubled regions from 3 to 6, added 17 representatives, redesigned incentives to cut variable compensation from 35% to 27% of Rx revenue, and centralized federal procurement via Lovell Government Services to save ~3% G&A.
Why this rating
Strong top-line acceleration (28% YoY, guidance raised to >30%) on $9.5M quarterly revenue is meaningful for $28M market-cap company; structural cost fixes and path to Adjusted EBITDA profitability Q3 2027 credible. Cash burn modest ($1.6M H1). Risks: cash runway ~2 years at current burn; execution of 2027 targets critical.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.